Health Care • Biotechnology: Pharmaceutical Preparations
$3.87 ▼ -0.13
(-3.25%)
MKT CAP: $180.8M • VOL: 534.4K
52W L $4 52W H $55
ROARABLE / RQD
D- • 38/100
PIOTROSKI
2 / 9
SION // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 |
|---|---|---|
| Revenue (Total Sales) | $0 | $0 |
| YoY Revenue Growth % | — | — |
| Gross Profit | — | — |
| Gross Margin % | — | — |
| Research & Development (R&D) | — | — |
| Operating Income (EBIT) | -$89.0M | -$70.6M |
| Operating Margin % | — | — |
| Net Income (GAAP) | -$75.3M | -$61.7M |
| EBITDA (Normalized) | -$88.7M | -$70.5M |
| Diluted EPS ($/sh) | — | — |
| Operating Cash Flow (OCF) | -$66.3M | -$52.8M |
| Capital Expenditures (CapEx) | $377.0K | $27.0K |
| Free Cash Flow (FCF) | -$66.7M | -$52.8M |
| FCF Margin % | — | — |
| Return on Invested Capital (ROIC %) | -28.3% | -45.0% |
| Cash & Short-Term Equivalents | $58.5M | $37.8M |
| Total Debt (Short + Long Term) | — | — |
| Total Stockholders' Equity | $306.8M | -$163.7M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SION.